Confectioner's shares look appetising on their lowly rating
Chocolates and snacks maker Zetar’s fall from grace since it bought baked snacks business Britannia has been galling for management and investors alike.
Floated as a shell with a buy-and-build strategy in 2005, the company’s shares had risen from 100p to a 590p peak by the spring of 2007 as it built a collection of confectionery and fruit and nut businesses. But in May that year, management made a departure from its strategy of buying profitable businesses when it forked out £4.7 million on baked snacks maker Britannia to further develop the healthy snacking offering.
The negative impact of this relatively small addition led to a share price collapse to 95p, with the market’s concerns about this loss-making division only heightened by the onset of recession and the collapse of major customer Woolworths.
‘[Britannia] was in the right product area, tapping into the healthy-eating market,’ explains chief executive Ian Blackburn, who was previously part of the successful acquisitive expansion of Perkins Foods a decade ago, ‘but it had a half-built factory and was losing money. We were in conversations with major brand houses for new products but it ended up being a distraction as the economy collapsed. When Woolworths went bust we were left with a bad debt of just under £1 million and at the same time our margins in natural snacks were being smashed by the dollar exchange rate.’
However, the market’s harsh reaction seems more akin to a company going bust, rather than one still poised to produce around 30p of annual earnings. And now, with natural snacking margins having come back and the Baked Snacks division sold back to its management for £2.7 million, Zetar’s prospects look much better.
Zetar’s confectionery arm generates the majority of group revenues, via the manufacture of private-label products for supermarkets (Marks & Spencer, Tesco and Sainsbury’s are its three largest customers) and licensing – making chocolates branded with The Simpsons, High School Musical, Barbie and the like – with the remaining sales derived from third-party manufacturing and its own brands.
A recent update from the company informed that a good Easter, when it increased its share of the chocolate egg market by almost 19 per cent to five per cent, had helped it to a strong year to April. This helped the confectionery arm lift revenues ten per cent to £75 million, exactly the same enlargement enjoyed by the natural and premium snacks arm, which produces fruit and nut mixes, yoghurt-covered raisins and so on, mainly under private labels for the same supermarket customers.
All in all, despite the loss of what would have been around £2 million to £3 million of business from Woolworths, Zetar says it will deliver a ten per cent increase in revenues from continuing activities to £119 million when results are unveiled in July.
However, while sales have been driven forward, it has been at the expense of margin, as the company has adapted to the new needs of recessionary Britain. Says Blackburn: ‘We have increased our levels of high-volume, lower-margin production. There is about £4 million to £5 million of new turnover in there derived from economy products.’
Nevertheless, he says that pre-tax profits should still be in line with the market’s £4.3 million forecast. Furthermore, even after £3.5 million of capital expenditure, a strict focus on costs enabled Zetar to reduce net debt to a better-than-expected £16 million.
Despite having picked itself up, the company’s shares still command only a lowly rating, trading on less than five times forecast consensus earnings of 33.2p for next year. Although some scepticism may persist as to whether the company can deliver its predicted earnings growth, Zetar continues to attract business from the supermarkets and major brand houses due to its flexible and innovative methods, and Blackburn mentions that ‘significant new business wins’ have been clinched for the group’s new value products. At 152.5p Zetar shares therefore look appetising. Buy.
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.